E
Entera Bio Ltd.
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of Entera Bio Ltd.
Revenue$0▼ 100.0% YoYFY 2023
Operating income−$8.9M▲ 31.7% YoY
Net profit−$8.9M▲ 32.0% YoY
Shareholders' equity$10.4M
Market cap$532MENTX · $3.06
Competitors10identified
About Entera Bio Ltd.
Sectors
Company details
- Founded
- 2018
- Listed
- Nasdaq: ENTX (since 2018)
Operational Areas of Entera Bio Ltd.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameEntera Bio Ltd.
TickerENTX
ExchangeNasdaq
CountryIsrael
SEC CIK0001638097
Listed since2018
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
ENTX · Nasdaq · SEC CIK 0001638097
Last price · 29 Oct 2026
$3.06
+6.99%
Market cap$532M
P/E9.9On FY 2023 diluted EPS
Volume203,531
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOIsraelListed 2018
ENTX share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Entera Bio Ltd.
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.